MRI Spectroscopy in Screening of Prostate Cancer

• Published in: Anticancer research Vol. 27; no. 1B; pp. 687 - 693
• Main Authors: GOEB, Katja, ENGEHAUSEN, Dirk G, KRAUSE, F. Steffen, HOLLENBACH, Hans-Peter, NIEDOBITEK, Gerald, BUETTNER, Maike, FRANGOU, Phroso, ENGELHARD, Karl
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01-01-2007
• Subjects: Aged; Biological and medical sciences; Choline - analysis; Citrates - analysis; Creatine - analysis; Humans; Magnetic Resonance Imaging - methods; Magnetic Resonance Spectroscopy - methods; Male; Mass Screening - methods; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - metabolism; Reproducibility of Results; Sensitivity and Specificity; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; MRI spectroscopy; Spectrometry; Urinary system disease; Cancerology; Prostate disease; Exploration; Medical imagery; Malignant tumor; Medical screening; Male genital diseases; Prostate cancer; Nuclear magnetic resonance imaging
• ISSN: 0250-7005; 1791-7530

Background: The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer
in comparison to T2-weighted MR imaging. Materials and Methods: Forty-six patients with biopsy confirmed prostate cancer underwent
combined endorectal-body-phased-array MRI at 1.5T (Tesla). Twelve patients were additionally examined with 3D-spectroscopy
sequence. The results of the spectroscopy were compared with the findings of T2-weighted MR imaging and the histological examination
of radical prostatectomy specimens. Results: With 3D-spectroscopy, a choline+creatine/citrate-ratio of 0.45 for healthy tissue
and a ratio of 1.90 for tumor tissue were found and a significant difference between the groups was demonstrated. In 6 cases
diagnosis of tumor localization was improved with spectroscopy in comparison with T2-weighted imaging alone. Conclusion: 3D-spectroscopy
is a suitable technique for improving MR imaging of prostate cancer. This method can improve the diagnostic accuracy of T2-weighted
imaging alone. At present, 3D-CSI spectroscopy alone can not be recommended with sufficient validity.